drugset / Trial / NCT01409915
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
A medicine that is FDA-approved for bone marrow stimulation (called Leukine) will be tested for its ability to be tolerated by Alzheimer's disease patients and potentially to improve their memory.
Timeline
- Start
- 2011-03
- Primary completion
- 2019-12-09
- Completion
- 2019-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |